Press Releases

Date Title View
Toggle SummaryNovember 7, 2017 GenMark Diagnostics to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 7, 2017-- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany , will present at the Canaccord Genuity Medical
View HTML
Toggle SummaryNovember 2, 2017 GenMark Diagnostics Reports Third Quarter 2017 Results
CARLSBAD, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the third quarter ended September 30, 2017 .
View HTML
Toggle SummaryOctober 19, 2017 GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017 . Management will hold a conference call to review the Company's financial performance starting
View HTML
Toggle SummaryOctober 19, 2017 GenMark Diagnostics Schedules Third Quarter 2017 Financial Results Conference Call for November 2, 2017
CARLSBAD, Calif. --(BUSINESS WIRE)--Oct. 19, 2017-- GenMark Diagnostics, Inc. (NASDAQ:GNMK) today announced that it plans to release its third quarter earnings results after market close on Thursday, November 2, 2017 . Management will hold a conference call to review the Company's financial
View HTML
Toggle SummaryAugust 1, 2017 GenMark Reports Second Quarter 2017 Results
Second Quarter Revenue of $12.4 million Ended the Quarter with Over 80 ePlex ® Instruments Installed at Customer Sites CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced
View HTML
Toggle SummaryJuly 31, 2017 GenMark Diagnostics to Attend Canaccord Genuity's 37th Annual Growth Conference
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that President and Chief Executive Officer, Hany Massarany , will attend the 2017 Canaccord Genuity Growth Conference in
View HTML
Toggle SummaryJune 29, 2017 GenMark Achieves CE Mark for its ePlex® Blood Culture Identification Gram-Positive and Gram-Negative Panels
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced it has achieved CE Mark under the European In-Vitro Diagnostic Devices Directive (98/79/EC) for its ePlex Blood Culture
View HTML
Toggle SummaryJune 13, 2017 GenMark Diagnostics Prices Upsized Public Offering of Common Stock
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced the upsizing and pricing of its previously announced underwritten public offering of 6,382,978 shares of its common stock
View HTML
Toggle SummaryJune 12, 2017 GenMark Diagnostics Commences Public Offering of Common Stock
CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today that it has commenced an underwritten public offering of $65,000,000 of shares of its common stock.
View HTML
Toggle SummaryJune 12, 2017 GenMark Receives FDA 510(k) Market Clearance for Its ePlex® Instrument and Respiratory Pathogen Panel
The True Sample-to-Answer Solution ™ Brings New Capabilities to Multiplex Molecular Diagnostics CARLSBAD, Calif. --(BUSINESS WIRE)-- GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that it has received
View HTML